Immunogenicity of a peptide‐based anti‐IgE conjugate vaccine in non‐human primates

The anti‐human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair®, Genentech, South San Fransisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (Cϵ3) of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Immun Inflamm Dis
Autors principals: Weeratna, Risini D., Chikh, Ghania, Zhang, Lu, Fraser, James D., Thorn, Jennifer M., Merson, James R., McCluskie, Michael J., Champion, Brian R., Davis, Heather L.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879460/
https://ncbi.nlm.nih.gov/pubmed/27957325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/iid3.98
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars